Summary & Overview
HCPCS J1212: Dimethyl Sulfoxide (DMSO) 50% Injection, 50 ml
HCPCS Level II code J1212 denotes an injectable formulation of dimethyl sulfoxide (DMSO) 50% in a 50 ml vial. This supply code is used in billing for the drug product itself and is relevant to facilities and clinicians administering DMSO via injection. Nationally, drug-specific HCPCS codes matter for accurate reimbursement, inventory tracking, and claims adjudication for injectable therapies.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what J1212 represents clinically and administratively, plus guidance on typical service settings. The publication provides benchmarks where available, notes on payer coverage patterns, and summaries of relevant policy or coding guidance that affect billing for injectable drug products. The content is intended to help coding and billing staff, practice managers, and compliance teams understand where J1212 fits within drug billing workflows and payer interactions.
Data not provided in the input (such as associated taxonomies, ICD-10 pairings, and related codes) is noted where applicable.
Billing Code Overview
HCPCS Level II code J1212 describes an injection of dimethyl sulfoxide (DMSO) 50%, supplied in a 50 ml vial. This code represents the billed product for the DMSO solution used for injection.
Service Type: Injectable drug administration
Typical Site of Service: Outpatient clinic or physician office (administration settings where injectable medications are provided).
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with localized interstitial cystitis or refractory bladder pain who presents to an outpatient urology clinic for intravesical therapy. The clinician reviews the patients history, confirms prior conservative treatments have failed, and obtains informed consent for intravesical instillation of dimethyl sulfoxide (DMSO) 50% solution (J1212). On the day of service the patient is placed supine on the exam table; a sterile technique catheterization of the bladder is performed, bladder emptied, and the 50 ml vial of DMSO 50% is instilled into the bladder via catheter. The solution is retained for a specified dwell time (commonly 1015 minutes) while the patient is monitored for immediate adverse reactions such as pain, local irritation, or systemic effects. After dwell time the bladder may be voided or the instilled solution drained. Documentation includes indication (e.g., interstitial cystitis), prior therapies, consent, catheterization procedure note, volume and concentration of DMSO instilled, dwell time, patient tolerance, and follow-up plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|